CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dextech Medical AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dextech Medical AB
Dag Hammarskjolds Vag 34A
Phone: +46 86131304p:+46 86131304 UPPSALA, 752 37  Sweden Ticker: DEXDEX
Business Summary
Dextech Medical AB is a Sweden-based research company specialized in urologic oncology. It is focused on prostate cancer, but also other cancers and non-malignant diseases. It develops drug canditates based on modified carbohydrate molecule combined with active substances. The Company has a patented technology platform, GuaDex, and three drug candidates with patents or patent applications. The portfolio includes: OsteoDex, for treatment of bone metastases in castration resistant prostate cancer (CRPC); SomaDex, based on endogenous hormone, somatostatin, and aimed at treatment of acromegaly, neuroendocrine tumors and palliative treatment of CRPC; and CatDex, for instillation treatment of bladder cancer.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20246/30/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board SvanteWadman 66 3/12/2013 9/2/2006
Chief Executive Officer, Director Anders R.Holmberg 68 8/9/2004 8/9/2004
Chief Financial Officer, Head of Investor Relations GoestaLundgren 69 1/1/2015
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1 (As of 6/30/2024)
Outstanding Shares: 18,485,857 (As of 9/30/2024)
Shareholders: 1,147
Stock Exchange: AKT


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024